Harnessing the Benefits of Externally Controlled Clinical Trials (ECTs) to Accelerate Development of Better Medicines
Parexel experts from regulatory, epidemiology and biostatistics discuss the use of external control arms (ECAs) as an alternative to randomized controlled trials (RCTs) to accelerate clinical development. Based on literature analysis, as well as available EMA and FDA guidelines, they provide a detailed assessment of ECAs pros and cons.
The digital era has enhanced the potential for real-world evidence (RWE) in regulatory decision-making, as demonstrated during the COVID-19 pandemic. Artificial intelligence (AI) could play a crucial role in analyzing RWE data to identify trends and important factors to control, potentially expanding ECA applications to dosage optimization, new administration routes, and accelerated treatment development. However, ECA implementation based on RWD still remains limited due to challenges such as ensuring data robustness, matching patient populations, and controlling bias.
What is more, regulatory acceptance of ECAs also requires thorough justification and early discussions with authorities to address potential biases and confounding factors. Therefore, while ECAs have the potential to streamline drug development and bring treatments to patients faster, further advancements in regulatory approaches, methodologies, and technologies are necessary to realize this goal fully.
Related Insights
Blog
The future of drug development: Leveraging EMA support for use of alternative nonclinical approaches
Jun 6, 2024
Blog
Regulatory acceptability of AI: Current perspectives
Mar 7, 2024
Blog
New EU pharmaceutical legislation: Strategic implications for drug developers
Feb 17, 2026
Blog
Assessing the need for comparative clinical trials in biosimilar development programs
Sep 21, 2023
Webinar
EU-CTR: Preparing for trial transition
Nov 30, 2023
Blog
Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market
Nov 13, 2023
Webinar
Breakthrough Devices Program: Where’s the value?
Nov 13, 2023
Whitepaper
Advancing clinical development through innovative trial design
Nov 3, 2023
Blog
Generative AI and how we can harness its power in clinical development
Sep 26, 2023
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Whitepaper
Scientific Validity Reports: a mandatory requirement for In Vitro Diagnostic Regulation (IVDR)
Sep 19, 2023
Blog
CMC flexibilities in biological medicinal product development: The current EU perspective
Jan 12, 2024
Related Insights
Blog
The future of drug development: Leveraging EMA support for use of alternative nonclinical approaches
Jun 6, 2024
Blog
Regulatory acceptability of AI: Current perspectives
Mar 7, 2024
Blog
New EU pharmaceutical legislation: Strategic implications for drug developers
Feb 17, 2026
Blog
Assessing the need for comparative clinical trials in biosimilar development programs
Sep 21, 2023
Webinar
EU-CTR: Preparing for trial transition
Nov 30, 2023
Blog
Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market
Nov 13, 2023
Webinar
Breakthrough Devices Program: Where’s the value?
Nov 13, 2023
Whitepaper
Advancing clinical development through innovative trial design
Nov 3, 2023
Blog
Generative AI and how we can harness its power in clinical development
Sep 26, 2023
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Whitepaper
Scientific Validity Reports: a mandatory requirement for In Vitro Diagnostic Regulation (IVDR)
Sep 19, 2023
Blog
CMC flexibilities in biological medicinal product development: The current EU perspective
Jan 12, 2024